Preoperative Radiotherapy for Breast Cancer

NeoRad Breast Cancer Study

Recruiting Phase 3 Interventional Study
Breast Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
1,826 (estimated)
Sponsor
Bielefeld University · Other
Who this trial is looking for

This trial is looking for women with invasive breast cancer who need radiotherapy after chemotherapy. Participants will receive radiotherapy before their surgery to see if it improves recovery and reduces side effects.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with invasive breast cancer
  • I need radiotherapy
  • I have signed the consent form for this trial
  • I am female
  • I am at least 18 years old
  • I have a performance status of 2 or less
  • I may have any hormone receptor and HER2 status
  • I have a cancer grade of G1-G3

You may not be able to join if

  • I am pregnant or breastfeeding
  • I have bilateral breast cancer
  • I have had prior radiotherapy to my chest
  • I have a connective tissue disease
  • I have chronic lung disease that is symptomatic
  • I have had a heart attack or heart failure
  • I have distant metastasis
  • I am male

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The NEORAD trial tests whether preoperative radiotherapy results in an improved DFS and less radiation induced late effect compared to postoperative radiotherapy in higher risk breast cancer after NACT.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Histologically proven invasive, unilateral breast cancer * Indication for radiotherapy * Indication for neoadjuvant chemotherapy (+/- antibody treatment or other targeted therapies) in accordance with national and international guidelines * Female * Informed consent for the tr…
Contacts

Christiane Matuschek, MD Prof.

+495215812901

christiane.matuschek@uni-bielefeld.de

CONTACT

Deborah Wöstenfeld, M. A.

+495215812972

deborah.woestenfeld@uni-bielefeld.de

CONTACT